49 results about "Regulatory molecules" patented technology

The invention provides a single molecule detection device and method based on an electrochemical gating technology in a quantum tunneling region, and relates to a detection technology for regulating molecular energy level alignment and regulating molecular conductance through gate voltage, a functionalized tunneling electrode is prepared at the tip of a nano pipettor and is placed in a solution containing single molecules, and the electrochemical gating technology in the quantum tunneling region is used for detecting the single molecules in the nano pipettor. The gate potential and the bias voltage are dynamically adjusted, tunneling current signals flowing through the single molecule are recorded and analyzed in real time, the structure, the charge state and the energy state of the single molecule can be actively regulated and controlled, and dynamic detection of the single molecule is achieved according to the conductivity change spectrum of the single molecule under different potential conditions. And the single molecule detection precision based on the tunneling electrode is obviously improved.

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

Described herein are compositions for modulating a molecule in a cell. Also described herein are methods for modulating a molecule in a cell.

The invention relates to the technical field of medicinal chemistry, radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a CDK4 / 6-targeted molecular imaging probe labeling precursor, a probe and a preparation method and application thereof. According to the molecular imaging probe [68Ga] Ga-PY03 provided by the invention, on the basis of a Ribociclib structure, a PEG1 chain and proline with envelope conformation are introduced, so that a hydrophobic region in a protein binding pocket can be filled, Van der Waals force can be enhanced, the molecular imaging probe [68Ga] Ga-PY03 can be stably bound with CDK4 / 6, and the targeting of the molecular imaging probe to the CDK4 / 6 is further ensured; the hydrophilicity of the molecular imaging probe can be adjusted, and kidney uptake is reduced; and the compound has excellent tumor / liver and tumor / muscle ratio, and can effectively improve tumor uptake.

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

The invention relates to the technical field of biological medicine, in particular to a cat triple vaccine immunologic adjuvant containing two cat interleukinins and a metabolism regulating molecule, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and metabolic regulation molecules, the metabolic regulation molecules comprise beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetylcysteine and L-carnitine, and the composition can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection capacity of vaccines, prolong the protection time of the vaccines and reduce adverse reactions; the vaccine can reduce or control reproduction infection of viruses in a more durable and higher level mode, the specific humoral immunity level and the memory response capacity of animals are remarkably improved, and invasion and diffusion of FPV, FCV and FHV-1 are better resisted.

The invention discloses an application of glycosylated phosphatidylinositol specific phospholipase D1 (GPLD1) as a sperm-egg recognition and / or binding regulation molecule.

The technology described herein is directed to Aptamer and Ribozyme Equilibrium Shifting (ARES) regions, including ON-switches and OFF-switches, which can be harnessed to regulate the stability of RNA molecules. Also described herein are compositions comprising such RNA molecules and methods of using them to regulate translation of cargo polypeptides.

The invention discloses an apparent editing target point method and application. Specifically, a method for regulating the expression level of a target gene and a nucleic acid binding molecule are provided, and the combination of the nucleic acid binding molecule and a gene expression regulating molecule has the ability to regulate the expression level of the target gene.

The invention is based on an immunomodulatory molecule, comprising an engineered protein binding domain, a linker and / or a hinge-region, and a domain for the activation and / or stimulation of an immune effector cell. The invention also pertains to an isolated nucleic acid comprising a sequence encoding for an immunomodulatory molecule according to this invention. Further provided is a method of obtaining a chimeric antigen receptor (CAR) expressing immune effector cell product, such as a CAR-T cell product, and / or a HLA-independent T cell receptor (HIT) expressing immune effector cell product, such as a HIT-T cell product, and / or a bispecific molecule expressing immune effector cell product, such as a bispecific T cell engager (BiTE) expressing immune effector cell product, comprising an immunomodulatory molecule, and / or a bispecific molecule, such as a BiTE, comprising an engineered protein binding domain. The invention also pertains to a product thereby obtainable, and to a pharmaceutical composition comprising the immunomodulatory molecule, the isolated nucleic acid, or the product obtainable by a method according to the present invention. Also provided is an immunomodulatory molecule, an isolated nucleic acid, a product, or a pharmaceutical composition according to this invention, for use in a method of diagnosis, prevention and / or treatment of a disease, or for preventing an organ transplant rejection, in a patient in need thereof.

The application discloses a kind of big steric hindrance C-C coupling palladium ligand and synthesis method, ligand is used naphthyl as the main group of stable ligand, this group provides big plane rigid configuration during ligand use, simultaneously, it provides big π electron for complex molecule to stabilize complex;In addition, the configuration of pyridofuran is used, the N coordination point of traditional N-P bidentate ligand is introduced O by furan this functional group in ortho position to adjust the chemical environment of intramolecular N coordination point, so as to modify the traditional N-P bidentate ligand to tridentate ligand, this change can effectively increase the penetration ability of Pd active center in actual ligand use to improve catalytic activity.

The invention discloses a benzothiazole non-condensed ring A-D-A '-D-A type organic solar cell acceptor material and a preparation method and application thereof, a benzothiazole unit is used as a central nuclear electron withdrawing unit (A-unit), and then the benzothiazole unit, the central nuclear electron withdrawing unit (A-unit), an electron donating unit (D-unit) and a terminal group are synthesized into the organic solar cell acceptor material with an A-D-A'-D-A structure. Wherein benzothiazole as an asymmetric central core structure can enhance the dipole moment of molecules, optimize the accumulation among the molecules and improve the blending property of a donor and an acceptor, and the characteristics can jointly promote charge transfer to inhibit the bimolecular recombination condition. The molecular morphology is regulated and controlled by connecting different structural groups to a top branched chain, and meanwhile, different atoms can be introduced into a benzene ring to regulate and control the chemical energy level. In addition, the polymer also has the characteristics that the aggregation behavior and the light absorption range of molecules can be adjusted by accessing different terminal groups. The benzothiazole-based non-fused ring A-D-A '-D-A type acceptor material provided by the invention is few in synthesis and preparation steps, simple in purification process and high in yield.

This invention discloses the application of the CEMIP-ITGA5 axis as a target in the preparation of products that regulate epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma, belonging to the fields of tumor molecular biology and precision medicine. Through TCGA-LUAD cohort bioinformatics analysis, immunohistochemical verification of clinical specimens, cell function experiments, and a nude mouse subcutaneous xenograft model, this invention discovers and confirms that the CEMIP-ITGA5 axis participates in regulating epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma. Specifically, CEMIP positively regulates ITGA5 expression, thereby promoting EMT, proliferation, migration, invasion, and in vivo tumorigenesis in lung adenocarcinoma cells. Based on this, the present invention provides two applications: Firstly, by detecting the expression levels of the dual genes CEMIP and ITGA5, a kit for assessing the risk of epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma can be prepared. The combined detection of CEMIP and ITGA5 can reflect the activation status of the CEMIP-ITGA5 axis at both the upstream regulatory molecule and downstream effector molecule levels, providing auxiliary molecular evidence for assessing EMT and metastasis-related risks in lung adenocarcinoma. Secondly, by targeting and inhibiting the expression or function of CEMIP and / or ITGA5, drugs can be prepared to inhibit epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma, effectively reversing the epithelial-mesenchymal transition phenotype and inhibiting tumor malignant progression. This invention provides novel molecular targets and technical solutions independent of known signaling pathways for prognostic assessment and targeted therapy of lung adenocarcinoma.

Aspects of the present invention include compositions and methods for discovering novel compositions and applying said compositions in treating medical conditions including aging, degenerative disease, and cancer through the modulation of molecular pathways regulating the regenerative and nonregenerative phenotypes of mammalian cells by means of globally or segmentally altering the embryonic-fetal and prenatal / postnatal transitional states of mammalian cells.

The present disclosure relates to genetically modified dendritic cells or their precursors expressing at least one antigen-derived peptide and at least one immunomodulatory molecule, their medical uses and methods of preparation. The present invention also relates to the production of CD49b producing IL-10 + LAG‑3+Tr1 cells or antigen-specific FOXP3 + In vitro methods for T cells, and related medical uses and pharmaceutical compositions.

The present invention discloses a multifunctional AIE optical diagnosis and treatment molecule and its azide compound, synthesis method and application. The multifunctional AIE optical diagnosis and treatment molecule uses triphenylamine as an electron donor and malononitrile fluorene as an electron acceptor. By adjusting the D-A structure of the molecule, a series of organic optical diagnosis and treatment molecules are synthesized, and a novel multifunctional optical diagnosis and treatment molecule with AIE properties is screened out. At the same time, further azide modification of the multifunctional optical diagnosis and treatment molecule can realize its covalent binding with functional groups such as polypeptides, DNA and small molecule compounds. The multifunctional AIE optical diagnosis and treatment molecule of the present invention has multifunctionality and can perform near-infrared fluorescence imaging, photodynamic therapy and photothermal therapy on tumors.

The present application relates to a kind of target protein conformation targeting regulatory molecules and regulatory methods in living cells.The protein conformation targeting regulatory molecules include: 1) with the targeting group of selectively binding target protein as skeleton, 2) two active functional groups are modified on the skeleton, c) rigid connecting arm introduced between targeting group and active functional group.Based on the above characteristics, after the protein conformation targeting regulatory molecules of the cell are incubated with cell, they are rapidly combined with target protein in cell specifically through cell membrane, and covalent reaction occurs with amino acid near binding pocket, to target the conformation of target protein is regulated.According to the difference of protein conformation and reaction site, different active groups and rigid connecting arm are used, to realize the accurate regulation of target protein conformation in different functional states.The present application provides important technical support in the field of exploring protein conformation and function, expanding the library of druggable proteins, researching new use of old drugs, disease treatment or prevention.

The present invention relates to the application of SOX13 as a gastric cancer biomarker. By constructing ferroptosis-resistant strains, the present invention uses a microarray to screen out SOX13 as an important regulatory molecule for gastric cancer ferroptosis sensitivity, and discovers that the anti-influenza drug zanamivir can specifically target the SOX13 protein. The present invention effectively verifies that the SOX13 gene is involved in the regulation of gastric cancer ferroptosis sensitivity, providing theoretical data for the ferroptosis sensitivity and chemosensitivity of gastric cancer cells. In addition, zanamivir can specifically target the SOX13 protein and reverse gastric cancer ferroptosis resistance, providing a theoretical basis for the treatment of ferroptosis resistance and chemoresistance of gastric cancer cells.

The present invention provides a single-molecule detection device and method based on electrochemical gating technology in the quantum tunneling region. It is a detection technology that regulates the alignment of molecular energy levels and adjusts molecular conductivity by regulating gate voltage. A functionalized tunneling electrode is prepared at the tip of a nanopipette and placed in a solution containing a single molecule. The gate potential and bias voltage are dynamically adjusted, and the tunneling current signal flowing through the single molecule is recorded and analyzed in real time. It can actively regulate the structure, charge state and energy state of the single molecule. According to the conductivity change spectrum of the single molecule under different potential conditions, dynamic detection of the single molecule is achieved, significantly improving the detection accuracy of single molecules based on tunneling electrode detection.

The technology described herein is directed to Aptamer and Ribozyme Equilibrium Shifting (ARES) regions, including ON-switches and OFF-switches, which can be harnessed to regulate the stability of RNA molecules. Also described herein are compositions comprising such RNA molecules and methods of using them to regulate translation of cargo polypeptides.

The invention relates to a downstream motion factor identification method and system for regulating brown fat metabolism and a storage medium, and relates to the technical field of bioinformatics, and the method comprises the following steps: (1) processing a sample and obtaining transcriptome original data; (2) difference analysis; (3) time sequence analysis; (4) enrichment analysis; (5) carrying out weighted gene co-expression network analysis; (6) machine learning; according to the method, downstream metabolism-promotion factors of brown adipocytes are identified by using RNA next-generation sequencing results, overall characteristics of transcriptomes are obtained through difference analysis, enrichment analysis and time sequence analysis, data are further reduced by using weighted gene co-expression network analysis and machine learning, and key regulatory genes are screened out; according to the invention, key regulation molecules capable of promoting metabolism of brown adipocytes can be found, and a new biological target is provided for treating obesity.

The present disclosure relates to compounds and methods for modulating the expression of c9orf72 (brain expressed, associated with NEDD4) and treating diseases and conditions in which c9orf72 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GGGGCC; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GGGGCC; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

The present disclosure relates to methods and compounds for treating genetic diseases, in particular, compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays a positive role. The compound may be a transcriptional regulating molecule having a first end, a second end, and an oligomeric backbone, wherein: a) the first end comprises a DNA binding moiety capable of non-covalently binding to a nucleotide repeat CAG or CTG; b) the second terminal comprises a protein binding moiety that binds to a regulatory molecule that modulates the expression of a gene comprising the nucleotide repeat CAG or CTG; and c) the oligomeric backbone comprises a linker between the first end and the second end.

The invention relates to the technical field of molecular biology. The invention provides a chicken reference gene EEF1A1 gene and / or FTH1 gene, and also provides an application of the EEF1A1 gene and / or FTH1 gene as a reference gene in chicken gene qualitative detection, and an application of the EEF1A1 gene and / or FTH1 gene as a reference gene in fluorescent quantitative detection of chicken in different development stages or different tissues. The new chicken reference gene disclosed by the invention has the characteristics of stability, extensiveness and sensitivity, can be effectively used for identifying and proving the functions of the gene and other regulatory molecules in biological pathways, and is beneficial to deeply understanding the functions of poultry genomes; biological characteristics and genetic mechanisms of poultry can be deeply understood; the accuracy of disease diagnosis is improved, and errors of a traditional method are reduced; in agricultural breeding, the method is helpful for identifying genes related to various production traits and screening and optimizing chicken varieties. The invention provides an important tool for biological research, agricultural breeding, transgenic animal research and the like.

The invention discloses a naphthalimide-based light diagnosis and treatment molecule with a controllable self-assembly behavior as well as a preparation method and application thereof, and relates to the technical field of near-infrared two-region light diagnosis and treatment. According to the functionalized light diagnosis and treatment molecular library based on the naphthalimide skeleton, the problems that the aggregation-induced performance of a traditional light diagnosis and treatment agent is reduced, the assembly controllability is insufficient, the structural characteristics, the accumulation mode and the performance adjustment are not clear and the like are solved by adjusting the molecular structure, the accumulation mode and the light physical performance of the traditional light diagnosis and treatment agent; the method is suitable for the field of near-infrared two-zone light diagnosis and treatment in biomedicine, and aims to improve the deep tissue imaging and treatment effect.

Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.

The invention discloses an apparent editing target point method and application. A method of modulating the expression level of a gene of interest and a nucleic acid binding molecule, the combination of which with a gene expression modulating molecule has the ability to modulate the expression level of a gene of interest.

The technology described herein is directed to Aptamer and Ribozyme Equilibrium Shifting (ARES) regions, including ON-switches and OFF-switches, which can be harnessed to regulate the stability of RNA molecules. Also described herein are compositions comprising such RNA molecules and methods of using them to regulate translation of cargo polypeptides.

The invention provides a novel miRNA target for treating AIDS (acquired immune deficiency syndrome) infection and cervical cancer and application of the novel miRNA target. The miRNA comprises miR-H1 (micro Ribonucleic Acid), miR-TAR (micro Ribonucleic Acid) and miR-N367, and is called HIV1-miRNAs for short. The HIV1-miRNAs exist in a cervical cancer patient suffering from HIV (Human Immunodeficiency Virus) infection. The HIV1-miRNAs can participate in the occurrence and development process of HIV combined cervical cancer by regulating and controlling tumor key pathways such as cell proliferation and inflammation in cervical cancer cells. The invention also provides regulatory molecules (including antisense nucleotides) for targeted regulation. The invention provides a new diagnosis and treatment way for clinical treatment and detection of HIV combined cervical cancer.

The disclosure provides polypeptides, polynucleotides, compositions, kits and methods useful for modulating RNA molecules including degrading disease-causing RNA(s) or stabilizing RNA(s) to treat diseases.